Novel strains and uses thereof

Abstract

The present invention relates to a strain selected from the group consisting of Saccharomyces cerevisiae KCTC14779BP, Saccharomyces cerevisiae KCTC14780BP, Lactobacillus fructivorans KCTC14776BP, Bacillus paramycoides KCTC14777BP and Bacillus megaterium KCTC14778BP; and a culture of said strain, a fermentation product of said strain and a fraction of said culture or fermentation product. In regard to a cosmetic composition, quasi-drug composition, or food composition containing one or more selected from the above, Saccharomyces cerevisiae, Lactobacillus fructivorans, Bacillus paramycoides, or Bacillus megaterium strains, cultures of the above strains, fermentation products of the above strains, or fractions of the cultures or fermentation products have excellent skin improvement and sensitive skin soothing effects, and therefore are highly useful as cosmetic compositions, quasi-drug compositions, and food compositions for improving skin. Therefore, various industrial applications such as cosmetics, quasi-drugs, and foods can be expected.

Description

[Technical Field]

[0001] The present invention relates to a strain selected from the group consisting of Saccharomyces cerevisiae KCTC14779BP, Saccharomyces cerevisiae KCTC14780BP, Lactobacillus fructivorans KCTC14776BP, Bacillus paramycoides KCTC14777BP, and Bacillus megaterium KCTC14778BP; and a cosmetic composition, quasi-drug composition, or food composition comprising at least one selected from the group consisting of the strain, a culture of the strain, a fermentation product of the strain, and a fraction of the culture or fermentation product. [Background technology]

[0002] Cosmetic ingredients are generally known to cause various skin problems such as inflammation, pimples, and edema (Maibach, HI, Contact Dermatitis, 6, 369-404, 1980). In addition, many of the substances used as raw materials for functional cosmetics have the problem of low stability or only a negligible effect on the skin.

[0003] For example, cosmetics known to improve skin wrinkles and elasticity include retinoids, adenosine, animal placenta-derived proteins, and chlorella extract. Retinol, the most widely known, has safety issues such as irritation when applied to the skin, so its usage amount is limited, and chlorella extract has only a small effect, so it is difficult to expect substantial effects of improving skin elasticity and improving wrinkles.

[0004] Inflammation occurs when cells or tissues are damaged for any reason, resulting in a series of defense mechanisms that minimize the damage and restore the damaged area to its original state. This triggers nerve, blood vessel, lymphatic, humoral, and cellular responses, resulting in pain, edema, redness, fever, and other functional disorders. Inflammation can be caused by physical factors such as trauma, frostbite, burns, and radiation; chemical factors such as acid; and immunological factors such as antibody responses. It can also be caused by vascular or hormonal imbalances. Various chemical mediators secreted by cells damaged by external stimuli cause vasodilation and increased permeability, allowing antibodies, complement, plasma, and phagocytes to gather at the inflamed area. This phenomenon causes erythema.

[0005] Anti-inflammatory agents are those that eliminate inflammation by eliminating the cause of inflammation and reducing biological reactions and symptoms. Substances currently used for anti-inflammatory purposes include non-steroidal agents such as flufenamic acid, ibuprofen, benzydamine, and indomethacin, and steroidal agents such as prednisolone and dexamethasone. However, most of these agents have issues with safety for the skin and stability when used in cosmetics, limiting their use.

[0006] Generally, moisturizing cosmetic compositions used on the skin maintain a certain amount of moisture in human hair, skin, etc., making them appear soft and lively, and preventing damage such as cracking and dryness. That is, cosmetic compositions for moisturizing the skin are used for the purpose of beautifying and maintaining the health of the skin and hair by supplying or maintaining a certain amount of moisture to the skin and hair.

[0007] Therefore, recently, much research has been conducted on cosmetic compositions that have excellent skin soothing, regenerating, moisturizing, antioxidant or anti-inflammatory effects, and have excellent effects in improving skin conditions (wrinkles, elasticity, etc.) and preventing skin aging or damage. [Prior art documents] [Non-patent literature]

[0008] Maibach.HI, Contact Dermatitis, 6.369-404, 1980 Summary of the Invention [Problem to be solved by the invention]

[0009] The present inventors conducted research into raw materials from natural resources that are safer and have superior skin-improving effects, and confirmed that a new strain of bacteria has skin-improving effects that are significantly superior to those of conventional yeast, Lactobacillus, and Bacillus fermentation products, thereby completing the present invention. [Means for solving the problem]

[0010] One object of the present invention is to provide a strain selected from the group consisting of Saccharomyces cerevisiae deposited under accession number KCTC14779BP, Saccharomyces cerevisiae deposited under accession number KCTC14780BP, Lactobacillus fructivorans deposited under accession number KCTC14776BP, Bacillus paramycoides deposited under accession number KCTC14777BP, and Bacillus megaterium deposited under accession number KCTC14778BP.

[0011] Another object of the present invention is to provide a cosmetic composition for improving skin, comprising at least one of the above strain, a culture of the above strain, a fermentation product of the above strain, and a fraction of the above culture or fermentation product.

[0012] Another object of the present invention is to provide a quasi-drug composition for improving skin, comprising at least one of the above-mentioned strain, a culture of the above-mentioned strain, a fermentation product of the above-mentioned strain, and a fraction of the above-mentioned culture or fermentation product.

[0013] Another object of the present invention is to provide a food composition for improving skin, comprising any one or more of the above-mentioned strain, a culture of the above-mentioned strain, a fermentation product of the above-mentioned strain, and a fraction of the above-mentioned culture or fermentation product.

[0014] Another object of the present invention is to provide a method for producing a fermented product, the method comprising a step of fermenting with a strain selected from the group consisting of Saccharomyces cerevisiae deposited under accession number KCTC14779BP, Saccharomyces cerevisiae deposited under accession number KCTC14780BP, Lactobacillus fructivorans deposited under accession number KCTC14776BP, Bacillus paramycoides deposited under accession number KCTC14777BP, and Bacillus megaterium deposited under accession number KCTC14778BP.

[0015] Another object of the present invention is to provide a method for producing a fraction, the method comprising the steps of culturing the Saccharomyces cerevisiae strain deposited under accession number KCTC14780BP; and separating water, C1-C4 alcohols, hexane, ethyl acetate, chloroform, or dichloromethane from the culture or fermentation product of the strain. [Effects of the Invention]

[0016] The Saccharomyces cerevisiae, Lactobacillus fructivorans, Bacillus paramycoides, or Bacillus megaterium strains of the present invention, cultures of the strains, fermentations of the strains, fermentations of the strains, or fractions of the cultures or fermentations have excellent skin-improving effects and are therefore highly useful as cosmetic compositions, quasi-drug compositions, and food compositions for improving skin. Therefore, they are expected to be used in a variety of industrial applications, such as cosmetics, quasi-drugs, and foods. DETAILED DESCRIPTION OF THE INVENTION

[0017] The present invention will be described in detail below. Meanwhile, the description and embodiment of one aspect disclosed in the present invention can be applied to the description and embodiment of a different aspect with respect to common features. Furthermore, all combinations of the various elements disclosed in the present invention fall within the scope of the present invention. Furthermore, the following specific description is not intended to limit the scope of the present invention.

[0018] One aspect of the present invention provides a strain selected from the group consisting of Saccharomyces cerevisiae deposited under accession number KCTC14779BP, Saccharomyces cerevisiae deposited under accession number KCTC14780BP, Lactobacillus fructivorans deposited under accession number KCTC14776BP, Bacillus paramycoides deposited under accession number KCTC14777BP, and Bacillus megaterium deposited under accession number KCTC14778BP.

[0019] The term "Saccharomyces cerevisiae" as used herein refers to a species of yeast belonging to the Saccharomycetaceae family and the genus Saccharomyces. This species has been widely used since ancient times, playing an important role in winemaking, breadmaking, and brewing. The characteristics of Saccharomyces cerevisiae vary depending on the growing region and natural environmental conditions, and the activity of the strain and its fermented product varies. The Saccharomyces cerevisiae of the present invention may be derived from a fermentation liquid, but is not limited thereto. Specifically, the Saccharomyces cerevisiae strain in the present invention may be, but is not limited to, the strain deposited under accession numbers KCTC14779BP or KCTC14780BP.

[0020] The term "Lactobacillus fructivorans" as used herein refers to a species of lactobacillus (lactic acid bacteria) belonging to the genus Fructilactobacillus, a positive bacterium. This species is found in wine, beer, grape must, dairy products, pickled cabbage, meat, and fish. The characteristics of Lactobacillus fructivorans vary depending on the growing region and natural environmental conditions, and the activity of the strain and its fermentation product varies. The Lactobacillus fructivorans of the present invention may be derived from a fermentation liquid, but is not limited thereto. Specifically, the Lactobacillus fructivorans strain in the present invention may be, but is not limited to, the strain deposited under KCTC14776BP.

[0021] The term "Bacillus paramycoides" as used herein refers to a Bacillus species belonging to the firmicutes. The characteristics of Bacillus paramycoides vary depending on the growing region and natural environmental conditions, and the strain and its fermentation product activity vary. The Bacillus paramycoides of the present invention may be derived from a fermentation broth, but is not limited thereto. Specifically, the Bacillus paramycoides strain of the present invention may be, but is not limited to, the strain deposited under KCTC14777BP.

[0022] The term "Bacillus megaterium (B. megaterium, B. subtilis, Priestia megaterium)" as used herein refers to a rod-shaped, Gram-positive, aerobic, spore-forming bacterium found primarily in a variety of habitats. It refers to a species of Bacillus belonging to the genera Bacillus and Priestia. It is widely used as a feed additive for poultry, livestock, aquatic animals, and ruminants. The characteristics of Bacillus megaterium vary depending on the growing region and natural environmental conditions, and the activity of the strain and its fermentation product varies. The Bacillus megaterium of the present invention may be derived from a fermentation liquid, but is not limited thereto. Specifically, the Bacillus megaterium strain in the present invention may be, but is not limited to, the strain deposited under KCTC14778BP.

[0023] In the present invention, the fermentation liquid can be produced by fermentation for 6 months to 2 years, specifically 9 months to 1 year and 6 months, and more specifically 1 year, and the fermentation liquid may be, but is not limited to, a plant fermentation liquid.

[0024] In one embodiment of the present invention, a fermentation liquid was prepared, and it was confirmed that the fermentation liquid of Saccharomyces cerevisiae, Lactobacillus fructivorans, Bacillus paramycoides, or Bacillus megaterium of the present invention has a superior skin-improving effect compared to the fermentation liquid of a general yeast, Saccharomyces cerevisiae, a general lactobacillus, Lactobacillus fructivorans, or a general bacillus, Bacillus paramycoides or Bacillus megaterium.

[0025] Another aspect of the present invention provides a cosmetic composition for improving skin, comprising any one or more of the above strain, a culture of the above strain, a fermentation product of the above strain, and a fraction of the above culture or fermentation product.

[0026] The term "strain" as used herein refers to a group of individuals derived from a single cell, propagated through asexual reproduction, and possessing the same genetic characteristics. A single species may contain multiple genetic variants with different genetic characteristics. In the present invention, the term "strain" refers to Saccharomyces cerevisiae, Lactobacillus fructivorans, Bacillus paramycoides, or Bacillus megaterium, and may specifically refer to one or more strains selected from the group consisting of Saccharomyces cerevisiae KCTC14779BP, Saccharomyces cerevisiae KCTC14780BP, Lactobacillus fructivorans KCTC14776BP, Bacillus paramycoides KCTC14777BP, and Bacillus megaterium KCTC14778BP, but is not limited thereto.

[0027] In the present invention, the bacterial strain may include bacterial cells, dried bacterial cells, or disrupted material of Saccharomyces cerevisiae, Lactobacillus fructivorans, Bacillus paramycoides, or Bacillus megaterium strains. In this case, the dried bacterial cells may be dried cells such as spray-dried cells, freeze-dried cells, vacuum-dried cells, or drum-dried cells, and the disrupted material may be a product obtained by disrupting the cell wall of the bacterial strain itself using chemical or physical forces.

[0028] The "culture" of the present invention refers to a product obtained by culturing the above-mentioned strain in a medium. For example, the culture of the present invention may include components remaining in a culture medium after culturing one or more strains selected from the group consisting of Saccharomyces cerevisiae, Lactobacillus fructivorans, Bacillus paramycoides, and Bacillus megaterium to obtain the strain, or may include components of the culture medium containing the strain.

[0029] The culture may be a whole culture, culture supernatant, lysate, or fraction thereof of the Saccharomyces cerevisiae, Lactobacillus fructivorans, Bacillus paramycoides, and / or Bacillus megaterium strains. In this case, the culture supernatant can be obtained by centrifuging the culture of the strain, the lysate can be obtained by physically or sonicating the strain, and the fraction can be obtained by subjecting the culture, culture supernatant, lysate, etc. to centrifugation, chromatography, or other methods.

[0030] The culture medium and other culture conditions used for culturing the strain of the present invention may be any medium used for culturing conventional microorganisms of the genus Saccharomyces, Lactobacillus, and / or Bacillus, without any particular limitations. Specifically, the strain of the present invention can be cultured in a conventional culture medium containing an appropriate carbon source, nitrogen source, phosphorus source, inorganic compounds, amino acids, and / or vitamins under aerobic or anaerobic conditions while adjusting the temperature, pH, etc.

[0031] In the present invention, the carbon source may include, but is not limited to, carbohydrates such as glucose, fructose, sucrose, maltose, etc.; sugar alcohols such as mannitol, sorbitol, etc.; organic acids such as pyruvic acid, lactic acid, citric acid, etc.; and amino acids such as glutamate, methionine, lysine, etc. In addition, natural organic nutrient sources such as starch hydrolysate, molasses, blackstrap molasses, rice bran, cassava, bagasse, and corn steeping liquid can be used. Carbohydrates such as glucose and sterilized pretreated molasses (i.e., molasses converted to reducing sugars) can also be used, and various other carbon sources can be used in appropriate amounts without limitation. These carbon sources can be used alone or in combination of two or more.

[0032] Examples of the nitrogen source include inorganic nitrogen sources such as ammonia, ammonium sulfate, ammonium chloride, ammonium acetate, ammonium phosphate, ammonium carbonate, and ammonium nitrate; and organic nitrogen sources such as amino acids, peptone, NZ-amine, meat extract, yeast extract, malt extract, corn steep liquor, casein hydrolysate, fish or its hydrolyzed products, defatted soybean cake or its hydrolyzed products, etc. These nitrogen sources may be used alone or in combination of two or more, but are not limited thereto.

[0033] The phosphorus source may include monopotassium phosphate, dipotassium phosphate, or the corresponding sodium-containing salts, etc. The inorganic compound may include sodium chloride, calcium chloride, iron chloride, magnesium sulfate, iron sulfate, manganese sulfate, calcium carbonate, etc.

[0034] In addition, the medium may contain amino acids, vitamins, and / or appropriate precursors. Specifically, the culture medium for the above-mentioned strains may be supplemented with L-amino acids. Specifically, glycine, glutamate, and / or cysteine ​​may be added, and if necessary, L-amino acids such as lysine may also be added, but the supplementation is not limited thereto.

[0035] The medium or precursor may be added to the culture in a batch or continuous manner, but is not limited thereto.

[0036] In the present invention, during the cultivation of the bacterial strain, compounds such as ammonium hydroxide, potassium hydroxide, ammonia, phosphoric acid, sulfuric acid, etc. can be added to the culture in an appropriate manner to adjust the pH of the culture. Furthermore, during the cultivation, antifoaming agents such as fatty acid polyglycol esters can be used to suppress the formation of bubbles. Furthermore, oxygen or an oxygen-containing gas can be injected into the culture to maintain an aerobic state, or nitrogen, hydrogen, or carbon dioxide gas can be injected without gas injection to maintain an anaerobic or microaerobic state.

[0037] The temperature of the culture water may be, but is not limited to, 25° C. to 40° C., more specifically, 28° C. to 37° C. The culture period can be continued until a desired amount of useful substance is produced, and specifically, may be, but is not limited to, 1 hour to 200 hours.

[0038] In the present invention, the term "fermentation" refers to the process in which microorganisms use their own enzymes to decompose organic matter, but is not a putrefaction reaction. Fermentation and putrefaction proceed through similar processes, but if useful substances are produced as a result of decomposition, it is called fermentation, and if foul odors or harmful substances are produced, it is called putrefaction.

[0039] In the present invention, the method for obtaining a fermented product from the above-mentioned strain is not particularly limited, and the fermented product can be obtained by inoculating the strain into a medium, culturing it with shaking at 20 to 40°C for 1 to 200 hours, separating the cells by centrifugation, and then disrupting the cells by ultrasonic treatment. Alternatively, the fermented product can be obtained by a method commonly used in the present technical field or a similar field.

[0040] In the present invention, the medium inoculated with the strain is not limited to a particular type as long as the strain can undergo fermentation.

[0041] In the present invention, the fermented product obtained from the above strain includes not only the fermented substance itself but also all kinds of substances including the fermented product generated from the above strain, such as a culture medium of the strain in which the strain and a culture coexist, a fermented product obtained by filtering the strain from the culture medium, a fermented product obtained by sterilizing the strain from the culture medium and filtering it, an extract obtained by extracting the fermented product or a culture medium containing the fermented product, a diluted solution obtained by diluting the fermented product or an extract thereof, a dried product obtained by drying the fermented product or an extract thereof, and a lysate obtained by collecting and disrupting the cells of the above strain.

[0042] As used herein, the term "fractionate" refers to the result of a fractionation method that separates a specific component or group from a mixture containing a variety of components.

[0043] In the present invention, the fractionation method for obtaining the fractions is not particularly limited and may be a method commonly used in the art. A non-limiting example of the fractionation method is a method in which a culture or fermentation product of a bacterial strain is extracted to obtain an extract, and the extract is treated with a predetermined solvent to obtain a fraction from the extract.

[0044] In the present invention, the type of solvent used to obtain the fraction is not particularly limited, and any solvent known in the art can be used. Non-limiting examples of the fractionation solvent include polar solvents such as water and alcohol; and non-polar solvents such as hexane, ethyl acetate, chloroform, and dichloromethane. These may be used alone or in combination. When an alcohol is used as the fractionation solvent, a C1 to C4 alcohol is preferably used.

[0045] In the present invention, the fraction may comprise polypeptides extracted from the culture or fermentation of the strain.

[0046] In the present invention, a peptide refers to a polymer in which amino acid units are artificially or naturally linked, and is a substance in which two or more amino acids are linked, and is called a tripeptide, oligopeptide, or polypeptide depending on the number of amino acids. Specifically, in the present invention, a polypeptide can refer to a substance containing 100 or more amino acids, but is not limited thereto.

[0047] In the present invention, "polypeptides extracted from a culture or fermentation product of a strain" refers to a culture or fermentation product obtained from a strain, and then functional peptide aggregates or polypeptides of a certain size or larger are separated from the culture or fermentation product. In the present invention, "polypeptides extracted from a culture or fermentation product of a strain" is used interchangeably with the terms "yeast polypeptide" or "fraction."

[0048] In the present invention, the method for separating a fraction from a fermentation product is not particularly limited. For example, the fraction can be obtained by fermenting a strain, disrupting the cells, concentrating the lysate, precipitating (solvent, centrifugation process), filtering the supernatant, and spray-drying it.

[0049] The term "skin improvement" in the present invention may refer to any one or more selected from the group consisting of skin moisturizing, wrinkle improvement, elasticity improvement, anti-aging, skin soothing, skin regeneration, skin inflammation improvement, skin whitening, anti-oxidation, anti-aging, skin protection from external stimuli, soothing of sensitive skin, sensitive skin improvement, erythema relief, itch relief, strengthening of skin barrier function, and skin irritation relief, but is not limited thereto.

[0050] The term "improvement" as used herein means any action that at least reduces a parameter related to the alleviation or treatment of a condition, for example, the severity of a symptom, and may include any one or more of skin moisturizing, wrinkle improvement, elasticity improvement, anti-aging, skin soothing, skin regeneration, skin inflammation improvement and skin whitening, anti-oxidation, anti-aging, skin protection from external stimuli, soothing of sensitive skin, sensitive skin improvement, erythema relief, itch relief, strengthening of skin barrier function, skin irritation relief, and skin pain relief.

[0051] The skin improvement may be achieved through, but is not limited to, the effects of promoting hyaluronic acid production, promoting collagen synthesis, enhancing cell activity, suppressing NO production, inhibiting melanin expression, scavenging free radicals, suppressing PGE2 (Prostaglandin E2) expression, increasing LOR (Loricrin) expression, suppressing TNF-α expression, or suppressing TRPV1 activity.

[0052] Specifically, the present inventors have confirmed that the fermentation product of Saccharomyces cerevisiae KCTC14779BP, the fermentation product of Saccharomyces cerevisiae KCTC14780BP and / or yeast polypeptides of the present invention, the fermentation product of Lactobacillus fructivorans KCTC14776BP, the fermentation product of Bacillus paramycoides KCTC14777BP, and the fermentation product of Bacillus megaterium KCTC14778BP have superior skin-improving effects compared to the fermentation products of general yeast, general lactobacillus, and general bacillus. More specifically, the fermentation product of Saccharomyces cerevisiae KCTC14779BP, the fermentation product of Saccharomyces cerevisiae KCTC14780BP and / or yeast polypeptides of the present invention, the fermentation product of Lactobacillus fructivorans KCTC14776BP, the fermentation product of Bacillus paramycoides KCTC14777BP, or the fermentation product of Bacillus megaterium KCTC14778BP have been confirmed to have excellent effects such as promoting collagen synthesis, promoting hyaluronic acid synthesis, promoting cell activity, suppressing NO production, inhibiting melanin expression, scavenging free radicals, suppressing PGE2 expression, increasing LOR expression, suppressing TNF-α expression, or suppressing TRPV1 activity.

[0053] Therefore, it has been confirmed that the Saccharomyces cerevisiae, Lactobacillus fructivorans, Bacillus paramycoides, Bacillus megaterium, and fermentation products thereof and / or fractions of the fermentation products of the present invention have superior skin-improving effects such as wrinkle improvement, elasticity improvement, anti-aging, skin moisturizing, skin soothing, skin regeneration, skin inflammation improvement, skin whitening, antioxidant, anti-aging, skin protection from external stimuli, soothing for sensitive skin, sensitive skin improvement, erythema relief, itching relief, strengthening of skin barrier function, skin irritation relief, and skin pain relief, compared to general yeast, general lactobacillus, general bacillus, or fermentation products thereof.

[0054] The term "wrinkles" as used herein can be broadly classified into expression wrinkles caused by facial muscles used to create facial expressions and fine wrinkles caused by general or localized skin atrophy. Specifically, wrinkles are caused by genetic factors, a decrease in collagen and elastic fibers in the dermis of the skin, external environment, etc. For purposes of the present invention, the term "wrinkles" is used to include both expression wrinkles and fine wrinkles, but is not limited thereto.

[0055] As used herein, the term "elasticity" refers to the ability of the skin to maintain firmness when pressed with a finger, and "improving elasticity" or "enhancing elasticity" refers to enhancing skin elasticity by strengthening the structure of the subcutaneous fat layer of an individual, and may refer to enhancing skin elasticity using the composition of the present invention.

[0056] The term "aging" as used herein refers to the phenomenon of deterioration of biological structures and functions over time, and the anti-aging of the present invention is not limited to the degree of improvement, as long as it prevents, inhibits, delays, or otherwise improves aging. In the present invention, wrinkle improvement and anti-aging may be achieved by promoting collagen synthesis, but are not limited thereto.

[0057] The term "collagen" as used herein refers to a fibrous protein found in abundance in many animals, especially mammals, and accounts for the majority of all connective tissues in the body, including skin and cartilage. Collagen is produced and secreted by fibroblasts, the most common cells in the body. Gelatin, which is widely used in cooking and in the food and pharmaceutical industries, is a product of the irreversible hydrolysis of collagen. Collagen loss is the main cause of wrinkles and reduced skin elasticity, so collagen synthesis is essential for wrinkle improvement and elasticity improvement.

[0058] In one embodiment of the present invention, it was confirmed that the yeast of the present invention, Saccharomyces cerevisiae KCTC14779BP fermentation product, Saccharomyces cerevisiae KCTC14780BP fermentation product, and / or yeast polypeptide, lactobacillus, Lactobacillus fructivorans KCTC14776BP fermentation product, or bacillus, Bacillus paramycoides KCTC14777BP fermentation product, had excellent collagen synthesis enhancement rates. As a result, the yeast fermentation product, yeast polypeptide, lactobacillus fermentation product, or bacillus fermentation product of the present invention was found to have significant effects on improving skin wrinkles and improving elasticity (Tables 3, 4, 5, and 6).

[0059] The term "skin moisturizing" as used herein refers to all actions that maintain skin flexibility by supplying moisture to the skin or blocking moisture evaporation, induce uniform exfoliation of keratin, and maintain a smooth surface, while "dryness" refers to a state in which such skin moisturizing is insufficient. The skin moisturizing effect helps improve wrinkles and increase skin elasticity. Specifically, skin moisturizing may be achieved by promoting the production of hyaluronic acid, but is not limited thereto.

[0060] The term "hyaluronic acid" as used herein refers to a type of glycosaminoglycan, a chain-like polymeric polysaccharide substance in which glucuronic acid and N-acetylglucosamine residues are repeatedly linked. Hyaluronic acid can contain 300 to 1,000 times its own weight in water and, by binding with water, exerts a moisturizing effect on the skin.

[0061] In one embodiment of the present invention, it was confirmed that the yeast fermentation product of the present invention, Saccharomyces cerevisiae KCTC14779BP, the fermentation product of Saccharomyces cerevisiae KCTC14780BP, the lactobacillus Lactobacillus fructivorans KCTC14776BP, the bacillus fermentation product of Bacillus paramycoides KCTC14777BP, or the bacillus fermentation product of Bacillus megaterium KCTC14778BP, had excellent hyaluronic acid synthesis enhancement rates. As a result, it was confirmed that the yeast fermentation product, yeast polypeptide, or bacillus fermentation product of the present invention has significant effects on anti-aging, skin moisturizing, etc. (Tables 7, 8, 9, 10, and 11).

[0062] The term "regeneration" as used herein means inhibiting functional decline of cells, tissues, or organs or restoring such declined functions. The functional decline of cells, tissues, or organs may be due to damage to the cells, tissues, or organs. Such damage may be caused by a variety of factors, including radiation therapy, drug therapy, surgery, infection, inflammation, degenerative diseases, autoimmune diseases, and aging. Meanwhile, the regeneration may be achieved by, but is not limited to, promoting cell differentiation. "Skin regeneration" as used herein means restoring damaged areas of skin tissue. Skin regeneration as used herein may be achieved by, but is not limited to, promoting cell activity.

[0063] In one embodiment of the present invention, while general yeast fermentation product had no effect on cell activity, the fermentation product of the yeast of the present invention, Saccharomyces cerevisiae KCTC14780BP, and / or yeast polypeptides were found to have significantly higher cell activity (Table 12).

[0064] The term "skin soothing" as used herein means to relieve and soothe erythema, itchiness, irritated skin or sensitive areas, and may be a concept including the relief of skin irritation. Examples include, but are not limited to, relief of skin itching, relief of skin pain, reduction of skin moisture loss and / or reduction of redness.

[0065] The term "inflammation" as used herein refers to a type of in vivo response to specific tissue damage or infection, with immune cells being the main mediators. The purpose of such inflammation is to minimize tissue damage, remove infectious agents, and promote tissue regeneration. In the present invention, skin soothing and regeneration may be achieved by, but is not limited to, suppressing NO production.

[0066] The term "NO (nitric oxide)" used in this invention plays a variety of roles, including eliminating bacteria and tumors, regulating blood pressure, and mediating neurotransmission. When an inflammatory response occurs, the expression of iNOS (inducible nitric oxide synthase) increases in related cells, producing large amounts of NO. Excessive NO production induces tissue damage, gene mutations, and nerve damage, and increases vascular permeability, promoting inflammatory responses such as edema. NO production increases in inflamed cells, while it is suppressed when the skin is calmed, demonstrating an essential correlation between the two.

[0067] In one embodiment of the present invention, it was confirmed that the fermentation product of the yeast Saccharomyces cerevisiae KCTC14780BP and / or yeast polypeptide or the fermentation product of the lactobacillus Lactobacillus fructivorans KCTC14776BP of the present invention had superior NO production inhibitory ability compared to general yeast or lactobacillus fermentation products. As a result, it was confirmed that the fermentation product of the yeast Saccharomyces cerevisiae KCTC14780BP and / or yeast polypeptide or the fermentation product of the lactobacillus Lactobacillus fructivorans KCTC14776BP of the present invention had skin soothing and anti-inflammatory effects (Tables 13 and 14).

[0068] In the present invention, the term "skin whitening" encompasses methods for increasing or maintaining the brightness of skin whose brightness has been reduced due to an excess of pigments such as melanin, as well as skin with increased brightness formed by the above methods, and specifically refers to skin whitening. The term "skin whitening" is understood as the improvement of symptoms caused by increased melanin, such as age spots and freckles, which are caused by the inhibition of melanin production due to the inhibition of tyrosinase activity.

[0069] In one embodiment of the present invention, the fermented product of Saccharomyces cerevisiae KCTC14780BP, which is the yeast of the present invention, and / or yeast polypeptide treatment exhibited excellent melanin production inhibition rate, thereby demonstrating skin whitening effects (Table 15).

[0070] In the present invention, the term "antioxidant" is meant to include all actions that inhibit oxidation, and specifically refers to, but is not limited to, the action of removing free radicals such as reactive oxygen species. Reactive oxygen oxidizes and destroys cells in the body, thereby exposing the body to various diseases. In addition, since the skin has developed a complex antioxidant defense network that acts to protect against reactive oxygen species, antioxidants can be associated with the effect of "protecting the skin from external stimuli."

[0071] The term "anti-aging" as used herein means to inhibit or slow the progression of aging. Cellular aging refers to cellular oxidation, and maintaining an appropriate amount of reactive oxygen is considered to be the main principle for preventing cellular oxidation and cellular aging.

[0072] In one embodiment of the present invention, the treatment with the yeast of the present invention, Saccharomyces cerevisiae KCTC14780BP fermentation product and / or yeast polypeptide, showed excellent free radical (reactive oxygen) scavenging effects, resulting in antioxidant, anti-aging, and skin protection effects against external stimuli (Table 16).

[0073] The term "sensitive skin" as used herein refers to skin that is more sensitive than normal skin to external irritants, allergens, or environmental changes or internal causes, and is therefore prone to irritation and dermatitis. It refers to various skin reactions such as erythema (redness), calluses, and blisters caused by external stimuli such as cosmetics and internal causes such as hormonal changes, as well as subjective symptoms such as itching, burning, irritation, pain, and hot flashes.

[0074] In one embodiment of the present invention, treatment with the yeast of the present invention, Saccharomyces cerevisiae KCTC14780BP fermentation product and / or yeast polypeptide, exhibited excellent effects of suppressing the expression of erythema / itch-inducing factor (PGE2), increasing the expression of LOR (Loricrin), a major component of the skin barrier, suppressing the expression of inflammatory cytokine (TNF-α), and suppressing the activity of cutaneous neurotransmitter (TRPV1), thereby alleviating typical symptoms of sensitive skin, such as erythema / itchiness and irritation / pain, and strengthening the skin barrier, thereby providing a soothing and / or improving effect on sensitive skin (Tables 17, 18, 19, and 20).

[0075] The term "cosmetic composition" of the present invention may be in a dosage form selected from the group consisting of, but is not limited to, a solution, an ointment for external use, a cream, a foam, a nourishing lotion, a softening lotion, a perfume, a pack, a softening lotion, a milky lotion, a makeup base, an essence, a soap, a liquid cleanser, a bath additive, a sunscreen cream, a sun oil, a suspension, an emulsion, a paste, a gel, a lotion, a powder, a soap, a surfactant-containing cleanser, an oil, a powder foundation, an emulsion foundation, a wax foundation, a patch, and a spray.

[0076] The cosmetic composition of the present invention may further contain one or more cosmetically acceptable carriers that are commonly blended in skin cosmetics, and may appropriately blend common ingredients such as oil, water, surfactant, moisturizer, lower alcohol, thickener, chelating agent, pigment, preservative, fragrance, etc., but is not limited thereto.

[0077] The cosmetically acceptable carrier contained in the cosmetic composition of the present invention varies depending on the formulation of the cosmetic composition.

[0078] When the cosmetic formulation of the present invention is an ointment, paste, cream, or gel, the carrier component may be, but is not limited to, animal oil, vegetable oil, wax, paraffin, starch, tragacanth, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide, etc. These may be used alone or in combination of two or more.

[0079] When the dosage form of the present invention is a solution or emulsion, a solvent, solubilizer, or emulsifier is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, etc., and particularly, cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil, sesame oil, glycerol aliphatic esters, polyethylene glycol, or sorbitan fatty acid esters, but is not limited thereto. These may be used alone or in combination of two or more.

[0080] When the dosage form of the present invention is a suspension, the carrier component may be, but is not limited to, a liquid diluent such as water, ethanol, or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, or polyoxyethylene sorbitan ester, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, or tragacanth, which may be used alone or in combination.

[0081] When the dosage form of the present invention is a soap, the carrier component may be, but is not limited to, an alkali metal salt of a fatty acid, a fatty acid hemiester salt, a fatty acid protein hydrolysate, isethionate, a lanolin derivative, a fatty alcohol, a vegetable oil, glycerol, or a sugar, which may be used alone or in combination of two or more.

[0082] When the dosage form of the present invention is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder, or a mixture thereof is used as a carrier component, and particularly when it is a spray, it may additionally contain a propellant such as chlorofluorohydrocarbon, propane / butane, or dimethyl ether.

[0083] In a specific embodiment of the present invention, there may be provided a cosmetic composition for wrinkle improvement, elasticity improvement, anti-aging or skin moisturizing, comprising Saccharomyces cerevisiae KCTC14779BP, but is not limited thereto.

[0084] In a specific embodiment of the present invention, a cosmetic composition for soothing skin, regenerating skin, alleviating skin inflammation, moisturizing skin, reducing wrinkles, improving elasticity, whitening skin, antioxidant, anti-aging, soothing sensitive skin, improving sensitive skin, alleviating erythema, alleviating pruritus, or strengthening skin barrier function, containing Saccharomyces cerevisiae KCTC14780BP, may be provided, but is not limited to these.

[0085] In a specific embodiment of the present invention, a cosmetic composition for wrinkle reduction, elasticity improvement, anti-aging, skin soothing, skin inflammation reduction, or skin moisturizing, containing Lactobacillus fructivorans KCTC14776BP, may be provided, but is not limited thereto.

[0086] In a specific embodiment of the present invention, there is provided a cosmetic composition for wrinkle improvement, elasticity improvement, anti-aging or skin moisturizing, comprising Bacillus paramycoides KCTC14777BP, but is not limited thereto.

[0087] In a specific embodiment of the present invention, a cosmetic composition for moisturizing skin may be provided, including, but not limited to, Bacillus megaterium KCTC14778BP.

[0088] Meanwhile, all of the ingredients described in the present invention may be contained in the composition of the present invention within a range that does not exceed the maximum use values ​​specified in regulations regarding cosmetic safety standards and China's "Cosmetic Safety and Technical Standards."

[0089] Another aspect of the present invention provides a quasi-drug composition for improving skin, comprising any one or more of the above-mentioned strain, a culture of the above-mentioned strain, a fermentation product of the above-mentioned strain, and a fraction of the above-mentioned culture or fermentation product.

[0090] The above-mentioned "Saccharomyces cerevisiae," "Lactobacillus fructivorans," "Bacillus paramycoides," "Bacillus megaterium," "strain," "culture," "fermentation," "fraction," "yeast polypeptide," "skin improvement," "improvement," "wrinkles," "elasticity," "collagen," "aging," "skin moisturizing," "hyaluronic acid," "regeneration," "skin soothing," "inflammation," "NO," "whitening," "antioxidant," "skin protection from external stimuli," "anti-aging," and "sensitive skin" are as described above.

[0091] The term "quasi-drug" as used herein may be selected from the group consisting of, but is not limited to, body cleansers, hand sanitizers, detergents, kitchen cleaners, cleaning detergents, toothpaste, mouthwashes, wet wipes, detergents, soaps, hand washes, hair cleansers, hair softeners, humidifier fillers, masks, ointments, and filter fillers.

[0092] The quasi-drug composition of the present invention may further contain, as necessary, a pharmaceutically acceptable carrier, excipient, or diluent in addition to the above-mentioned components. The pharmaceutically acceptable carrier, excipient, or diluent is not limited as long as it does not impair the effects of the present invention, and may include, for example, a filler, extender, binder, wetting agent, disintegrant, surfactant, lubricant, sweetener, flavoring agent, preservative, etc.

[0093] Representative examples of pharmaceutically acceptable carriers, excipients, or diluents of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, maltitol, starch, gelatin, glycerin, gum acacia, alginate, calcium phosphate, calcium carbonate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, mineral oil, propylene glycol, polyethylene glycol, vegetable oils, injectable esters, witepsol, macrogol, Tween 61, cocoa butter, lauric butter, and the like.

[0094] When the culture, fermentation product thereof, or fraction of the culture or fermentation product of the present invention is used as a quasi-drug, it may further contain one or more active ingredients exhibiting the same or similar functions. For example, known ingredients for promoting beneficial skin bacteria, inhibiting harmful skin bacteria, soothing the skin, alleviating skin inflammation, whitening the skin, regenerating the skin, and healing wounds may be included. The inclusion of additional ingredients for wrinkle reduction, whitening the skin, alleviating skin troubles, and moisturizing the skin further enhances the wrinkle reduction, elasticity improvement, skin moisturizing, anti-aging, soothing the skin, regenerating the skin, and alleviating skin inflammation of the composition of the present invention. When adding these ingredients, consideration should be given to skin safety when used in combination, ease of formulation, and stability of the active ingredients.

[0095] The quasi-drug composition of the present invention may further comprise one or more ingredients selected from the group consisting of skin anti-aging or moisturizing ingredients known in the art, such as retinoic acid, TGF, animal placenta-derived protein, betulinic acid, and chlorella extract; non-steroidal anti-inflammatory ingredients known in the art, such as flufenamic acid, ibuprofen, benzydamine, indomethacin, prednisolone, dexamethasone, allantoin, azulene, and hydrocortisone; and derivatives thereof and various plant extracts. The additional ingredients may be included in an amount of 0.0001% to 10% by weight of the total composition, and the above content range can be adjusted depending on factors such as skin safety and ease of formulation of the strain, culture, or fermentation product of the strain of the present invention, or a fraction extracted from the fermentation product of the strain.

[0096] The formulation method, dosage, method of use, constituents, etc. of quasi-drugs can be appropriately selected from conventional techniques known in the technical field.

[0097] In a specific embodiment of the present invention, there is provided a quasi-drug composition for wrinkle improvement, elasticity improvement, anti-aging or skin moisturizing, which contains Saccharomyces cerevisiae KCTC14779BP, but is not limited thereto.

[0098] In a specific embodiment of the present invention, a quasi-drug composition for soothing skin, regenerating skin, alleviating skin inflammation, moisturizing skin, reducing wrinkles, improving elasticity, whitening skin, antioxidant, anti-aging, soothing sensitive skin, improving sensitive skin, alleviating erythema, alleviating pruritus, or strengthening skin barrier function, containing Saccharomyces cerevisiae KCTC14780BP, may be provided, but is not limited to this.

[0099] In a specific embodiment of the present invention, a quasi-drug composition for wrinkle reduction, elasticity improvement, anti-aging, skin soothing, skin inflammation reduction, or skin moisturizing, containing Lactobacillus fructivorans KCTC14776BP, can be provided, but is not limited thereto.

[0100] In a specific embodiment of the present invention, there is provided a quasi-drug composition for wrinkle improvement, elasticity improvement, anti-aging or skin moisturizing, comprising Bacillus paramycoides KCTC14777BP, but is not limited thereto.

[0101] In a specific embodiment of the present invention, a quasi-drug composition for moisturizing skin may be provided, including, but not limited to, Bacillus megaterium KCTC14778BP.

[0102] Another aspect of the present invention provides a food composition for improving skin, comprising any one or more of the above-mentioned strain, a culture of the above-mentioned strain, a fermentation product of the above-mentioned strain, and a fraction of the above-mentioned culture or fermentation product.

[0103] The above-mentioned "Saccharomyces cerevisiae," "Lactobacillus fructivorans," "Bacillus paramycoides," "Bacillus megaterium," "strain," "culture," "fermentation," "fraction," "yeast polypeptide," "skin improvement," "improvement," "wrinkles," "elasticity," "collagen," "aging," "skin moisturizing," "hyaluronic acid," "regeneration," "skin soothing," "inflammation," "NO," "whitening," "antioxidant," "skin protection from external stimuli," "anti-aging," and "sensitive skin" are as described above.

[0104] The term "food" as used herein includes all foods in the ordinary sense, such as meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, drinking water, tea, health supplements, alcoholic beverages, vitamin complexes, and functional health foods, and is not limited thereto, as long as it includes one or more strains selected from the group consisting of Saccharomyces cerevisiae KCTC14779BP, Saccharomyces cerevisiae KCTC14780BP, Lactobacillus fructivorans KCTC14776BP, Bacillus paramycoides KCTC14777BP, and Bacillus megaterium KCTC14778BP of the present invention, cultures of the strains, fermentation products of the strains, and fractions of the cultures or fermentation products. In addition, the present invention can be prepared by adding the strain, culture of the strain, fermentation product of the strain, or fraction of the culture or fermentation product to soup, tea, jelly, juice, etc., which are prepared using the strain as a main ingredient, and may be in the form of pills, powder, granules, tablets, capsules, or liquid.

[0105] The term "functional food" is similar to "food for special health use (FoSHU)" and refers to a food with high medical and therapeutic effects that is processed to efficiently exert bioregulatory functions in addition to providing nutrients. Here, "functional" refers to obtaining beneficial health effects, such as regulating nutrients or exerting physiological effects on the structure and function of the human body. The food of the present invention can be prepared by methods commonly used in the art, and can be prepared by adding raw materials and ingredients commonly used in the art. Furthermore, the dosage form of the food can be any dosage form recognized as a food. The food composition of the present invention can be prepared in various dosage forms, and unlike general medicines, it has the advantage of being made from food ingredients, eliminating side effects that can occur with long-term drug administration, and is highly portable. The food of the present invention can be taken as an adjuvant to enhance immune-boosting effects.

[0106] The term "health food" refers to food that has more active health maintenance and promotion effects than general foods, and "health supplement food" refers to food intended for health supplementation. In some cases, the terms "health functional food," "health food," and "health supplement" are used interchangeably.

[0107] Specifically, the health functional foods are foods made by adding one or more strains selected from the group consisting of Saccharomyces cerevisiae KCTC14779BP, Saccharomyces cerevisiae KCTC14780BP, Lactobacillus fructivorans KCTC14776BP, Bacillus paramycoides KCTC14777BP, and Bacillus megaterium KCTC14778BP, cultures of the strains, fermentation products of the strains, and fractions of the cultures or fermentation products to food ingredients such as beverages, teas, spices, gum, and confectioneries, or by encapsulating, powdering, or manufacturing them into suspensions. These foods are meant to provide specific health benefits when ingested, but unlike general medicines, they have the advantage of being made from food ingredients and are free of side effects that can occur when taking medicines for a long period of time.

[0108] The composition may further contain a physiologically acceptable carrier, but the type of carrier is not particularly limited, and any carrier commonly used in the art may be used.

[0109] The composition may also contain additional ingredients commonly used in food compositions to improve odor, taste, or visual appearance. For example, vitamins A, C, D, E, B1, B2, B6, and B12, niacin, biotin, folate, and panthotenic acid may be included. Minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), copper (Cu), and chromium (Cr) may also be included. Amino acids such as lysine, tryptophan, cysteine, and valine may also be included.

[0110] The composition may also contain food additives such as preservatives (potassium sorbate, sodium benzoate, salicylic acid, sodium dehydroacetate, etc.), disinfectants (bleaching powder, high-strength bleaching powder, sodium hypochlorite, etc.), antioxidants (butylhydroxyanisole (BHA), butylhydroxytoluene (BHT), etc.), colorants (tar dyes, etc.), color formers (sodium nitrite, sodium acetate, etc.), bleaching agents (sodium sulfite), seasonings (MSG, monosodium glutamate, etc.), sweeteners (dulcin, cyclomate, saccharin, sodium, etc.), flavorings (vanillin, lactones, etc.), leavening agents (alum, potassium D-bitartrate, etc.), strengtheners, emulsifiers, thickeners (thickeners), coating agents, gum bases, foam inhibitors, solvents, and improvers. The additives are selected according to the type of food and used in appropriate amounts.

[0111] The Saccharomyces cerevisiae KCTC14779BP, Saccharomyces cerevisiae KCTC14780BP, Lactobacillus fructivorans KCTC14776BP, Bacillus paramycoides KCTC14777BP, or Bacillus megaterium KCTC14778BP strain, a culture of the strain, a fermentation product of the strain, or a fraction of the culture or fermentation product may be added directly or in combination with other foods or food ingredients, as appropriate, according to conventional methods. The amount of active ingredient to be added can be determined depending on the intended use (prevention, health, or therapeutic treatment). Generally, during the production of foods or beverages, the food composition of the present invention can be added in an amount of 50 parts by weight or less, specifically 20 parts by weight or less, to the food or beverage. However, for long-term consumption for health and hygiene purposes, the active ingredient may be added in an amount less than the above range without any safety issues, and therefore the active ingredient may be used in an amount greater than the above range.

[0112] An example of the food composition of the present invention is a health drink composition. In this case, various flavorings or natural carbohydrates may be added as additional ingredients, as in conventional beverages. The natural carbohydrates may be monosaccharides such as glucose and fructose; disaccharides such as maltose and sucrose; polysaccharides such as dextrin and cyclodextrin; or sugar alcohols such as xylitol, sorbitol, and erythritol. The sweetener may be a natural sweetener such as thaumatin or stevia extract; or an artificial sweetener such as saccharin or aspartame. The proportion of the natural carbohydrate is generally about 0.01 to 0.04 g, specifically about 0.02 to 0.03 g, per 100 mL of the composition of the present invention.

[0113] In addition to the above, the health drink composition may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid, pectic acid salts, alginic acid, alginic acid salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, or carbonation agents. Fruit pulp may also be included for the production of natural fruit juice, fruit juice drinks, or vegetable drinks. These ingredients may be used independently or in combination. The proportion of these additives is not critical, but is typically selected from the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.

[0114] Specifically, the food composition may contain one or more of Saccharomyces cerevisiae KCTC14779BP, Saccharomyces cerevisiae KCTC14780BP, Lactobacillus fructivorans KCTC14776BP, Bacillus paramycoides KCTC14777BP, or Bacillus megaterium KCTC14778BP strains, cultures of the above strains, fermentations of the above strains, and fractions of the above cultures or fermentations in an amount of 0.00001 to 100% by weight based on the total weight of the food composition.

[0115] In a specific embodiment of the present invention, there is provided a food composition for wrinkle improvement, elasticity improvement, anti-aging or skin moisturizing, which contains Saccharomyces cerevisiae KCTC14779BP, but is not limited thereto.

[0116] In a specific embodiment of the present invention, a food composition for soothing skin, regenerating skin, alleviating skin inflammation, moisturizing skin, reducing wrinkles, improving elasticity, whitening skin, antioxidant, anti-aging, soothing sensitive skin, improving sensitive skin, alleviating erythema, alleviating pruritus, or strengthening skin barrier function, containing Saccharomyces cerevisiae KCTC14780BP, may be provided, but is not limited to these.

[0117] In a specific embodiment of the present invention, a food composition for wrinkle reduction, elasticity improvement, anti-aging, skin soothing, skin inflammation reduction, or skin moisturizing, containing Lactobacillus fructivorans KCTC14776BP, may be provided, but is not limited thereto.

[0118] In a specific embodiment of the present invention, there is provided a food composition for wrinkle improvement, elasticity improvement, anti-aging or skin moisturizing, comprising Bacillus paramycoides KCTC14777BP, but is not limited thereto.

[0119] In a specific embodiment of the present invention, a food composition for moisturizing skin may be provided, including, but not limited to, Bacillus megaterium KCTC14778BP.

[0120] Another aspect of the present invention provides a method for producing a fermented product, the method including a step of fermenting with a strain selected from the group consisting of Saccharomyces cerevisiae deposited under accession number KCTC14779BP, Saccharomyces cerevisiae deposited under accession number KCTC14780BP, Lactobacillus fructivorans deposited under accession number KCTC14776BP, Bacillus paramycoides deposited under accession number KCTC14777BP, and Bacillus megaterium deposited under accession number KCTC14778BP.

[0121] The above "Saccharomyces cerevisiae," "Lactobacillus fructivorans," "Bacillus paramycoides," "Bacillus megaterium," "strain," and "fermented product" are as described above.

[0122] In the present invention, Saccharomyces cerevisiae KCTC14779BP, Saccharomyces cerevisiae KCTC14780BP, Lactobacillus fructivorans KCTC14776BP, Bacillus paramycoides KCTC14777BP, or Bacillus megaterium KCTC14778BP can be cultured in a medium at 20°C to 40°C for 1 to 200 hours with shaking, followed by centrifugation to separate the cells and ultrasonication to disrupt the cells, to produce a fermented product, but this is not limiting. The medium used in the present invention may be MRS medium, R2A medium, or LBS medium, but the type of medium is not limited as long as it allows the strain to be cultured or fermented.

[0123] Another aspect of the present invention provides a method for producing a fraction, the method comprising the steps of culturing the Saccharomyces cerevisiae strain deposited under accession number KCTC14780BP; and separating water, C1 to C4 alcohols, hexane, ethyl acetate, chloroform, or dichloromethane from a culture or fermentation product of the strain.

[0124] The above "Saccharomyces cerevisiae," "strain," and "fraction" are as described above.

[0125] In another aspect of the present invention, a cosmetic composition comprising any one or more of the strains of the present invention, cultures of the strains, fermentations of the strains, and fractions of the cultures or fermentations is provided for use in improving skin.

[0126] In another aspect of the present invention, a quasi-drug composition comprising at least one of the strain of the present invention, a culture of the strain, a fermentation product of the strain, and a fraction of the culture or fermentation product is provided for use in improving skin.

[0127] In another aspect of the present invention, a food composition comprising any one or more of the strains of the present invention, cultures of the strains, fermentations of the strains, and fractions of the cultures or fermentations is provided for use in improving skin.

[0128] The above "strain," "culture," "fermentation product," "fraction," "yeast polypeptide," "skin improvement," and "improvement" are as described above.

[0129] Another aspect of the present invention provides a method for improving skin, comprising the step of applying or administering to an individual a composition containing, as an active ingredient, any one or more of the strains of the present invention, cultures of the strains, fermentations of the strains, and fractions of the cultures or fermentations.

[0130] The above "strain," "culture," "fermentation product," "fraction," "yeast polypeptide," "skin improvement," and "improvement" are as described above.

[0131] The term "individual" as used herein means any animal, including humans, and the animal may be any mammal, such as a cow, horse, sheep, pig, goat, camel, antelope, dog, or cat, that requires treatment for symptoms similar to those of humans, but is not limited thereto.

[0132] In the present invention, the term "application" means any method of contacting the composition according to the present invention with the skin of an individual in any suitable manner, with the aim of allowing the composition to be absorbed into the skin.

[0133] When the composition of the present invention is applied to the skin of an individual, it can have the effects of wrinkle improvement, elasticity improvement, anti-aging, skin moisturizing, skin soothing, skin regeneration, skin inflammation improvement, skin whitening, antioxidant, anti-aging, soothing sensitive skin, sensitive skin improvement, erythema relief, itching relief, and strengthening of skin barrier function, and the method can include applying or administering the composition to an individual in an amount effective to exhibit the above effects.

[0134] In the present invention, the term "administration" is a general term for providing a predetermined substance to an individual by any appropriate method, and the administration route may be any common route as long as it can reach the target skin.

[0135] The present invention will be described in more detail with reference to the following examples. However, these examples are for illustrative purposes only and the scope of the present invention is not limited to these examples.

[0136] Example 1. Isolation of yeast (Saccharomyces cerevisiae KCTC14779BP, KCTC14780BP), Lactobacillus (Lactobacillus fructivorans KCTC14776BP), and Bacillus (Bacillus paramycoides KCTC14777BP, Bacillus megaterium KCTC14778BP) strains From the plant fermentation liquid that had been fermented for one year, novel yeast strains, Saccharomyces cerevisiae CF2-0w-17 and CF2-0w-22, Lactobacillus fructivorans CF2-2w-20, Bacillus paramycoides CF1-0w-14, and Bacillus megaterium CF1-w2-30, were isolated.

[0137] The above-mentioned Saccharomyces cerevisiae CF2-0w-17 and CF2-0w-22 strains were deposited with the Korea College of Biotechnology and Technology (KCTC), a depository institution under the Budapest Treaty, on November 16, 2021, and were assigned accession numbers KCTC14779BP and KCTC14780BP. The above-mentioned strains were confirmed to have the 18s rRNA base sequences of SEQ ID NOs: 1 and 2, respectively.

[0138] The above-mentioned Lactobacillus fructivorans CF2-2w-20, Bacillus paramycoides CF1-0w-14, and Bacillus megaterium CF1-w2-30 strains were deposited with the Korea Institute of Biotechnology and Technology (KCTC), a depository institution under the Budapest Treaty, on November 16, 2021, and were assigned accession numbers KCTC14776BP, KCTC14777BP, and KCTC14778BP. The above strains were confirmed to have the 16s rRNA base sequences of SEQ ID NOs: 3, 4, and 5, respectively.

[0139] Example 2. Production of yeast, Lactobacillus, and Bacillus fermentates and polypeptides extracted from the fermentates Example 2-1. Preparation of yeast (Saccharomyces cerevisiae KCTC14779BP, KCTC14780BP) fermented products Saccharomyces cerevisiae KCTC14779BP and KCTC14780BP strains were inoculated into medium, cultured with shaking, and then centrifuged to separate the cells. The cells were suspended in purified water and disrupted by sonication to produce Saccharomyces cerevisiae KCTC14779BP or KCTC14780BP fermentation products. The specific conditions and composition are shown in Table 1 below.

[0140] [Table 1]

[0141] Example 2-2. Preparation of polypeptides extracted from yeast (Saccharomyces cerevisiae KCTC14780BP) fermentation product and fractions containing the polypeptides The Saccharomyces cerevisiae KCTC14780BP strain was inoculated into a medium and cultured with shaking. The cells were separated by centrifugation to obtain a lysate, which was then concentrated. The lysate was then suspended in alcohol in an amount twice the volume of the lysate, and centrifuged to separate the precipitated polypeptide fraction, thereby producing a fraction containing the yeast Saccharomyces cerevisiae KCTC14780BP polypeptide of the present invention.

[0142] Example 2-3. Preparation of Lactobacillus (Lactobacillus fructivorans KCTC14776BP), Bacillus (Bacillus paramycoides KCTC14777BP, Bacillus megaterium KCTC14778P) fermentation products Lactobacillus fructivorans KCTC14776BP, Bacillus paramycoides KCTC14777BP, and Bacillus megaterium KCTC14778P strains were inoculated into medium, cultured with shaking, and then centrifuged to separate the bacterial cells. The bacterial cells were suspended in purified water and disrupted by ultrasonic treatment to finally produce Lactobacillus fructivorans KCTC14776BP, Bacillus paramycoides KCTC14777BP, and Bacillus megaterium KCTC14778P fermentation products. The specific conditions and composition are shown in Table 2 below.

[0143] [Table 2]

[0144] Example 3. Confirmation of collagen synthesis promoting effects of yeast, Lactobacillus, and Bacillus fermentation products Example 3-1. Confirmation of the collagen synthesis promoting effect of yeast (Saccharomyces cerevisiae KCTC14779BP) fermentation product Human dermal fibroblasts were treated with each sample at each concentration for 48 hours. The collagen synthesis rate was measured using a procollagen type 1C-peptide (PIP) EIA kit. The collagen synthesis efficacy of the sample was calculated by comparing it with the negative control (DMEM containing 0% serum).

[0145] To confirm the collagen synthesis-enhancing effect of Saccharomyces cerevisiae KCTC14779BP fermentation product, we compared the collagen synthesis rates of normal cells, normal cells treated with TGF-β, treated with Saccharomyces cerevisiae KCTC14779BP yeast fermentation product, and treated with normal yeast (Saccharomyces cerevisiae KCTC 7296) fermentation product (Table 3).

[0146] [Table 3]

[0147] As shown in Table 3, the collagen synthesis rate was increased when Saccharomyces cerevisiae KCTC14779BP fermentation was treated with general cells. The increase rate of Saccharomyces cerevisiae KCTC14779BP fermentation was greater than that of general yeast fermentation produced under similar conditions.

[0148] Example 3-2. Confirmation of the collagen synthesis promoting effect of yeast (Saccharomyces cerevisiae KCTC14780BP) fermentation product and fraction containing yeast polypeptide The collagen synthesis promotion effect was confirmed using the same method as in Example 3-1 above, and the collagen synthesis rates were compared when general cells were treated with TGF-β, Saccharomyces cerevisiae KCTC14780BP fermentation product, and fractions containing yeast polypeptides (Table 4).

[0149] [Table 4]

[0150] As shown in Table 4, the collagen synthesis rate was increased when general cells were treated with the fermentation product of Saccharomyces cerevisiae KCTC14780BP and the fraction containing yeast polypeptides. Compared to the general yeast fermentation product prepared under similar conditions, the collagen synthesis rate of the fermentation product of Saccharomyces cerevisiae KCTC14780BP and the fraction containing yeast polypeptides was superior.

[0151] Example 3-3. Confirmation of the collagen synthesis enhancing effect of lactobacillus (Lactobacillus fructivorans KCTC14776BP) fermentation product The collagen synthesis promotion effect was confirmed in the same manner as in Example 3-1 above, and the collagen synthesis rates were compared between normal cells, normal cells treated with TGF-β, treated with Lactobacillus fructivorans KCTC14776BP fermentation product, and treated with normal lactobacillus (Lactobacillus plantarum KCTC 3108) fermentation product (Table 5).

[0152] [Table 5]

[0153] As shown in Table 5, the collagen synthesis rate was confirmed to increase when Lactobacillus fructivorans (KCTC14776BP) fermentation was treated with general Lactobacillus cells. The increase rate of Lactobacillus fructivorans (KCTC14776BP) fermentation was greater than that of general Lactobacillus fermentation produced under similar conditions.

[0154] Example 3-4. Confirmation of collagen synthesis promoting effect of Bacillus (Bacillus paramycoides KCTC14777BP) fermentation product The collagen synthesis promotion effect was confirmed in the same manner as in Example 3-1 above, and the collagen synthesis rates were compared between normal cells, normal cells treated with TGF-β, Bacillus paramycoides KCTC14777BP fermentation product, and normal bacillus (Bacillus megaterium KCTC 3007) fermentation product (Table 6).

[0155] [Table 6]

[0156] As shown in Table 6, the collagen synthesis rate was increased when Bacillus paramycoides KCTC14777BP fermentation was treated with general cells. The increase rate of Bacillus paramycoides KCTC14777BP fermentation was greater than that of general Bacillus fermentation produced under similar conditions.

[0157] As a result, it was found that the fermented product of Saccharomyces cerevisiae KCTC14779BP, Saccharomyces cerevisiae KCTC14780BP and fraction containing yeast polypeptides, and the fermented product of Lactobacillus fructivorans KCTC14776BP and / or Bacillus paramycoides KCTC14777BP of the present invention exhibit excellent effects in improving skin wrinkles and increasing elasticity.

[0158] Example 4: Confirmation of the hyaluronic acid synthesis enhancing effect of yeast, Lactobacillus, and Bacillus fermentation products Example 4-1. Confirmation of the hyaluronic acid synthesis enhancing effect of yeast (Saccharomyces cerevisiae KCTC14779BP) fermentation product Human keratinocytes (HaCaT) were treated with each sample at each concentration for 72 hours. Hyaluronic acid synthesis was measured using R&D Systems' Quantikine ELISA Hyaluronan, and the moisturizing ability was quantified by comparing it with the control group (treated with DMEM containing 0% serum) (Table 7).

[0159] [Table 7]

[0160] As shown in the results in Table 7, it was confirmed that the rate of hyaluronic acid synthesis increased when Saccharomyces cerevisiae KCTC14779BP fermentation was treated with general cells. The rate of increase in Saccharomyces cerevisiae KCTC14779BP fermentation was even greater than that in general yeast fermentation produced under similar conditions.

[0161] Example 4-2. Confirmation of the hyaluronic acid synthesis enhancing effect of yeast (Saccharomyces cerevisiae KCTC14780BP) fermentation product The effect of promoting hyaluronic acid synthesis was confirmed in the same manner as in Example 4-1 above (Table 8).

[0162] [Table 8]

[0163] As shown in the results in Table 8 above, it was confirmed that the hyaluronic acid synthesis rate increased when Saccharomyces cerevisiae KCTC14780BP fermentation product was treated with general cells compared to the control group. In addition, the hyaluronic acid synthesis rate of Saccharomyces cerevisiae KCTC14780BP fermentation product was superior to that of general yeast fermentation product produced under similar conditions.

[0164] Example 4-3. Confirmation of the hyaluronic acid synthesis enhancing effect of lactobacillus (Lactobacillus fructivorans KCTC14776BP) fermentation product The effect of promoting hyaluronic acid synthesis was confirmed in the same manner as in Example 4-1 above (Table 9).

[0165] [Table 9]

[0166] As shown in the results in Table 9 above, it was confirmed that the rate of hyaluronic acid synthesis increased when Lactobacillus fructivorans KCTC14776BP fermentation was treated with general cells. The increase rate of Lactobacillus fructivorans KCTC14776BP fermentation was even greater than that of general Lactobacillus fermentation produced under similar conditions.

[0167] Example 4-3. Confirmation of the hyaluronic acid synthesis enhancing effect of Bacillus (Bacillus paramycoides KCTC14777BP) fermentation product The effect of promoting hyaluronic acid synthesis was confirmed in the same manner as in Example 4-1 above (Table 10).

[0168] [Table 10]

[0169] As shown in the results in Table 10, it was confirmed that the rate of hyaluronic acid synthesis increased when Bacillus paramycoides KCTC14777BP fermentation was treated with general cells. The rate of increase in Bacillus paramycoides KCTC14777BP fermentation was greater than that in general Bacillus fermentation produced under similar conditions.

[0170] Example 4-4. Confirmation of the hyaluronic acid synthesis enhancing effect of Bacillus (Bacillus megaterium KCTC14778BP) fermentation product The effect of promoting hyaluronic acid synthesis was confirmed in the same manner as in Example 4-1 above (Table 11).

[0171] [Table 11]

[0172] As shown in the results in Table 11 above, it was confirmed that the rate of hyaluronic acid synthesis increased when the fermentation product of Bacillus megaterium KCTC14780BP was treated with general cells. The increase rate of the fermentation product of Bacillus megaterium KCTC14778BP was even greater than that of the fermentation product of general Bacillus produced under similar conditions.

[0173] As a result, it was found that the fermentation product of Saccharomyces cerevisiae KCTC14779BP, Saccharomyces cerevisiae KCTC14780BP, Lactobacillus fructivorans KCTC14776BP, Bacillus paramycoides KCTC14777BP and / or Bacillus megaterium KCTC14778BP of the present invention exhibits excellent effects such as improving skin wrinkles, increasing elasticity, moisturizing, and soothing the skin.

[0174] Example 5. Confirmation of the cell activity enhancing effect of yeast (Saccharomyces cerevisiae KCTC14780BP) fermentation product and fractions containing yeast polypeptides Human dermal fibroblasts were treated with each sample at each concentration for 48 hours. Cell activity was measured using a CCK-8 kit. The cell activity of the sample was calculated by comparing it with the negative control (DMEM containing 0% serum).

[0175] To confirm the cell activity-enhancing effects of Saccharomyces cerevisiae KCTC14780BP fermentation product and fractions containing yeast polypeptides, the cell activity rates were compared among normal cells, normal cells treated with FBS, treated with Saccharomyces cerevisiae KCTC14780BP fermentation product, treated with normal yeast (Saccharomyces cerevisiae KCTC 7296) fermentation product, and treated with fractions containing yeast (Saccharomyces cerevisiae KCTC14780BP) polypeptides (Table 12).

[0176] [Table 12]

[0177] As shown in the results in Table 12 above, cell activity was confirmed to increase when fermented with Saccharomyces cerevisiae KCTC14780BP and a fraction containing yeast (Saccharomyces cerevisiae KCTC14780BP) polypeptides with general cells. Compared to general yeast fermentation prepared under similar conditions, the increase in activity of Saccharomyces cerevisiae KCTC14780BP fermentation and a fraction containing yeast polypeptides was even greater.

[0178] As a result, it was found that the fermentation product of Saccharomyces cerevisiae KCTC14780BP and the fraction containing yeast polypeptide of the present invention exhibited excellent effects on cell activity, etc.

[0179] Example 6: Confirmation of the skin soothing and anti-inflammatory effects (inhibition of NO production) of yeast and lactobacillus fermentation products Example 6-1. Confirmation of the skin soothing and anti-inflammatory effects (inhibition of NO production) of yeast (Saccharomyces cerevisiae KCTC14780BP) fermentation product and fraction containing yeast polypeptide Raw 264.7 cells were treated with 1 μg / ml LPS diluted to each concentration and cultured for 24 hours. The NO production inhibitory activity was evaluated using the NO quantification kit as follows (Table 13).

[0180] NO production inhibitory capacity (%) = (1 - (NO production amount when sample is added / NO production amount when sample is not added) x 100

[0181] [Table 13]

[0182] As shown in the results in Table 13, the NO production inhibitory activity increased when general cells were treated with the fermentation product of Saccharomyces cerevisiae KCTC14780BP and a fraction containing yeast polypeptides. The increase rate of the fermentation product of Saccharomyces cerevisiae KCTC14780BP was greater than that of the general yeast fermentation product prepared under similar conditions.

[0183] Example 6-2. Confirmation of the skin soothing and anti-inflammatory effects (inhibition of NO production) of fermented lactobacillus (Lactobacillus fructivorans KCTC14776BP) The skin soothing and inflammation-relieving effects were confirmed in the same manner as in Example 6-1 above (Table 14).

[0184] [Table 14]

[0185] As shown in the results in Table 14 above, it was confirmed that the NO production inhibitory ability increased when Lactobacillus fructivorans KCTC14776BP fermentation was treated with general cells. The increase rate of Lactobacillus fructivorans KCTC14776BP fermentation was greater than that of general Lactobacillus fermentation produced under similar conditions.

[0186] As a result, it was found that the Saccharomyces cerevisiae KCTC14780BP fermentation product and the fraction containing yeast polypeptide and / or the Lactobacillus fructivorans KCTC14776BP fermentation product of the present invention exhibit excellent effects such as skin soothing and inflammation relief.

[0187] Example 7: Confirmation of the melanin expression inhibitory effect of yeast (Saccharomyces cerevisiae KCTC14780BP) fermentation product and fractions containing yeast polypeptides B16f10 melanocytes were cultured with each diluted sample for 72 hours, and the amount of melanin present in the melanocytes was then quantified. The melanin production inhibition rate was calculated as a percentage of total protein, and the DMSO control group (0% serum-containing DMEM, untreated group, negative control group) was set at 100%.

[0188] To measure the degree of reduction in melanin pigment levels in the fermented product of Saccharomyces cerevisiae KCTC14780BP and the fraction containing yeast polypeptides, the melanin production inhibition rates were compared between the positive control (Arbutin 200 ppm (Lim YJ et al., 2009, Arch Pharm Res.)), the Saccharomyces cerevisiae KCTC14780BP fermented product treatment, and the fraction containing yeast polypeptides treatment (Table 15).

[0189] [Table 15]

[0190] As shown in the results in Table 15 above, it was confirmed that the melanin production inhibition rate increased when ordinary cells were treated with the fermented product of Saccharomyces cerevisiae (KCTC14780BP) and the fraction containing yeast polypeptide.

[0191] As a result, it was found that the fermentation product of Saccharomyces cerevisiae KCTC14780BP and the fraction containing yeast polypeptide of the present invention exhibit excellent effects on skin whitening.

[0192] Example 8. Confirmation of the free radical scavenging effect of yeast (Saccharomyces cerevisiae KCTC14780BP) fermentation product and fractions containing yeast polypeptides

[0193] After dissolving the sample in DMSO, the same amount (100 μl) of 0.15 mM DPPH solution and the sample were mixed and reacted at room temperature for 30 minutes. Then, the color change of DPPH was measured by measuring the absorbance (A540) at 540 nm.

[0194] To evaluate the radical scavenging ability of Saccharomyces cerevisiae KCTC14780BP fermentation product and fractions containing yeast polypeptides, IC50 values ​​were calculated by measuring A540 values ​​after treatment with a positive control (Vitamin C), Saccharomyces cerevisiae KCTC14780BP fermentation product, and fractions containing yeast polypeptides, and the radical scavenging ability was compared (Table 16).

[0195] [Table 16]

[0196] As shown in the results of Table 16 above, the free radical (reactive oxygen) scavenging effect was confirmed when ordinary cells were treated with the fermented product of Saccharomyces cerevisiae KCTC14780BP and the fraction containing yeast polypeptides.

[0197] As a result, it was found that the fermented product of Saccharomyces cerevisiae KCTC14780BP of the present invention has excellent antioxidant, anti-aging and skin protection effects against external stimuli.

[0198] Example 9: Confirmation of the soothing effect of a fraction containing yeast polypeptide from yeast (Saccharomyces cerevisiae KCTC14780BP) on sensitive skin Example 9-1. Confirmation of the inhibitory effect of yeast polypeptide-containing fractions on the expression of erythema / itch-inducing factor (PGE2) Raw 264.7 cells were diluted to various concentrations and treated with UVB (11 mJ) and cultured for 24 hours. The inhibitory effect (%) of PGE2 (prostaglandin E2) production was evaluated using a PGE2 quantification kit. Specifically, a standard curve was created using 4PL regression, and the UVB-induced PGE2 production effect was calculated as 100%, and the relative amount of PGE2 produced during sample treatment was calculated and measured (Table 17).

[0199] [Table 17]

[0200] As shown in the results of Table 17 above, the inhibitory effect of PGE2 expression was confirmed when a fraction containing Saccharomyces cerevisiae KCTC14780BP polypeptide was treated in normal cells.

[0201] As a result, it was found that the fraction containing the yeast polypeptide of the present invention exhibits excellent effects such as alleviating skin erythema / itchiness, and soothing and improving sensitive skin.

[0202] Example 9-2. Confirmation of the effect of yeast polypeptide-containing fractions on increasing the expression of LOR (Loricrin), a major component in strengthening the skin barrier HaCaT cells were treated with TNF-α (10 pg / ml) for 3 hours, and then the samples were diluted to various concentrations and mixed with the TNF-α-treated HaCaT cells and cultured for 24 hours. The increase in expression of loricrin (LOR), a major component of the skin barrier, was quantified using qPCR (Table 18).

[0203] [Table 18]

[0204] As shown in the results in Table 18 above, it was confirmed that LOR expression increased when normal cells were treated with a fraction containing the Saccharomyces cerevisiae KCTC14780BP polypeptide.

[0205] As a result, it was found that the fraction containing the yeast polypeptide of the present invention exhibits excellent effects such as strengthening the skin barrier and soothing and improving sensitive skin.

[0206] Example 9-3. Confirmation of the inflammatory cytokine suppression effect of fractions containing yeast polypeptides HaCaT cells were cultured for 24 hours after dilution and treatment with UVB (11 mJ). The expression levels of inflammatory cytokines (TNF-α) expressed in sensitive skin were calculated using qPCR (Table 19).

[0207] [Table 19]

[0208] As shown in the results in Table 19 above, it was confirmed that TNF-α expression was suppressed when normal cells were treated with a fraction containing Saccharomyces cerevisiae KCTC14780BP polypeptide.

[0209] As a result, it was found that the fraction containing the yeast polypeptide of the present invention exhibits excellent effects such as soothing and improving sensitive skin.

[0210] Example 9-4. Confirmation of the inhibitory effect of yeast polypeptide-containing fractions on the activity of the skin neurotransmitter TRPV1 The samples were diluted to various concentrations and treated in HEK 293T-TRPV1 cells. After 10 minutes, the inhibitory effect on TRPV1 (Transient receptor potential vanilloid-1) activity was evaluated using a calcium influx detection assay kit (Table 20).

[0211] [Table 20]

[0212] As shown in the results in Table 20 above, TRPV1 activity was inhibited when normal cells were treated with a fraction containing Saccharomyces cerevisiae KCTC14780BP polypeptide. This was confirmed to be more effective than the positive control group treated under similar conditions.

[0213] As a result, it was found that the fraction containing the yeast polypeptide of the present invention exhibits excellent effects in reducing cutaneous neurological irritation / pain, soothing and improving sensitive skin, etc.

[0214] From the above description, those skilled in the art to which the present invention pertains will understand that the present invention may be embodied in other specific forms without changing the technical spirit or essential characteristics thereof. In this regard, it should be understood that the above-described embodiments are merely illustrative and not limiting. The scope of the present invention is not limited to the above detailed description, but should encompass any modifications or variations derived from the meaning and scope of the claims below and their equivalents.

Claims

1. A strain selected from the group consisting of Saccharomyces cerevisiae deposited under accession number KCTC14780BP, Saccharomyces cerevisiae deposited under accession number KCTC14779BP, Lactobacillus fructivorans deposited under accession number KCTC14776BP, Bacillus paramycoides deposited under accession number KCTC14777BP, and Bacillus megaterium deposited under accession number KCTC14778BP.

2. A cosmetic composition for improving skin, comprising at least one of the strain according to claim 1, a culture of said strain, a fermentation product of said strain, and a fraction of said culture or fermentation product.

3. The cosmetic composition according to claim 2, wherein the fractions are fractionated into water, C1 to C4 alcohols, hexane, ethyl acetate, chloroform, or dichloromethane from a culture or fermentation product of the Saccharomyces cerevisiae strain deposited under accession number KCTC14780BP.

4. The cosmetic composition according to claim 2, which is a cosmetic composition for improving wrinkles, improving elasticity, or moisturizing skin, comprising Saccharomyces cerevisiae deposited under accession number KCTC14779BP.

5. The cosmetic composition according to claim 2, which contains Saccharomyces cerevisiae deposited under accession number KCTC14780BP and is used for skin soothing, skin regeneration, skin inflammation relief, skin moisturizing, wrinkle relief, skin elasticity improvement, skin whitening, antioxidant properties, anti-aging, sensitive skin soothing, sensitive skin improvement, erythema relief, itching relief, or skin barrier function strengthening.

6. The cosmetic composition according to claim 2, which is a cosmetic composition for improving wrinkles, improving elasticity, soothing the skin, improving skin inflammation, or moisturizing the skin, and contains Lactobacillus fructivorans deposited under accession number KCTC14776BP.

7. The cosmetic composition according to claim 2, which is a cosmetic composition for improving wrinkles, improving elasticity, or moisturizing skin, comprising Bacillus paramycoides deposited under accession number KCTC14777BP.

8. The cosmetic composition according to claim 2, which is a cosmetic composition for improving wrinkles, improving elasticity, or moisturizing skin, comprising Bacillus megaterium deposited under accession number KCTC14778BP.

9. A quasi-drug composition for improving skin, comprising at least one of the strain according to claim 1, a culture of said strain, a fermentation product of said strain, and a fraction of said culture or fermentation product.

10. The composition described in claim 9, wherein the quasi-drug composition is a quasi-drug composition for improving wrinkles, improving elasticity or moisturizing the skin, comprising Saccharomyces cerevisiae deposited under deposit number KCTC14779BP.

11. The composition according to claim 9, wherein the quasi-drug composition comprises Saccharomyces cerevisiae deposited under deposit number KCTC14780BP and is a quasi-drug composition for skin soothing, skin regeneration, improving skin inflammation, skin moisturizing, improving wrinkles, improving elasticity, skin whitening, antioxidant, anti-aging, soothing sensitive skin, improving sensitive skin, alleviating erythema, alleviating pruritus, or strengthening skin barrier function.

12. The composition described in claim 9, wherein the quasi-drug composition is a quasi-drug composition for improving wrinkles, improving elasticity, soothing the skin, improving skin inflammation or moisturizing the skin, comprising Lactobacillus fructivorans deposited under deposit number KCTC14776BP.

13. The composition described in claim 9, wherein the quasi-drug composition is a quasi-drug composition for improving wrinkles, improving elasticity, or moisturizing the skin, comprising Bacillus paramycoides deposited under deposit number KCTC14777BP.

14. The composition described in claim 9, wherein the quasi-drug composition is a quasi-drug composition for improving wrinkles, improving elasticity, or moisturizing the skin, comprising Bacillus megaterium deposited under deposit number KCTC14778BP.

15. A food composition for improving skin, comprising at least one of the strain according to claim 1, a culture of said strain, a fermentation product of said strain, and a fraction of said culture or fermentation product.

16. The composition described in claim 15, wherein the food composition is a food composition for improving wrinkles, improving elasticity, or moisturizing the skin, comprising Saccharomyces cerevisiae deposited under accession number KCTC14779BP.

17. The composition according to claim 15, wherein the food composition comprises Saccharomyces cerevisiae deposited under deposit number KCTC14780BP and is a food composition for soothing skin, regenerating skin, improving skin inflammation, moisturizing skin, improving wrinkles, improving elasticity, whitening skin, antioxidant, anti-aging, soothing sensitive skin, improving sensitive skin, alleviating erythema, alleviating pruritus, or strengthening skin barrier function.

18. The composition described in claim 15, wherein the food composition is a food composition for improving wrinkles, improving elasticity, soothing the skin, improving skin inflammation or moisturizing the skin, comprising Lactobacillus fructivorans deposited under deposit number KCTC14776BP.

19. The composition described in claim 15, wherein the food composition is a food composition for improving wrinkles, improving elasticity, or moisturizing the skin, comprising Bacillus paramycoides deposited under accession number KCTC14777BP.

20. The composition described in claim 15, wherein the food composition is a food composition for improving wrinkles, improving elasticity, or moisturizing the skin, comprising Bacillus megaterium deposited under accession number KCTC14778BP.

21. A method for producing a fermented product, comprising a step of fermenting with a strain selected from the group consisting of Saccharomyces cerevisiae deposited under accession number KCTC14780BP, Saccharomyces cerevisiae deposited under accession number KCTC14779BP, Lactobacillus fructivorans deposited under accession number KCTC14776BP, Bacillus paramycoides deposited under accession number KCTC14777BP, and Bacillus megaterium deposited under accession number KCTC14778BP.

22. Cultivating the Saccharomyces cerevisiae strain deposited under accession number KCTC14780BP; and A method for producing a fraction comprising the step of separating a culture or fermentation product of the strain with water, a C1-C4 alcohol, hexane, ethyl acetate, chloroform or dichloromethane.

Images